17:46 , Sep 7, 2018 |  BC Week In Review  |  Financial News

Non-coding RNA company Twentyeight-Seven debuts with $65M

Twentyeight-Seven Therapeutics Inc. (Cambridge, Mass.) raised $65 million on Sept. 6 in a series A round co-led by MPM Capital and Novartis Venture Fund. Johnson & Johnson Innovation-JJDC Inc., Vertex Ventures HC, Longwood Fund and...
21:22 , Sep 6, 2018 |  BC Extra  |  Financial News

Non-coding RNA company Twentyeight-Seven debuts with $65M

Twentyeight-Seven Therapeutics Inc. (Cambridge, Mass.) raised $65 million in a series A co-led by MPM Capital and Novartis Venture Fund. Johnson & Johnson Innovation-JJDC Inc., Vertex Ventures HC, Longwood Fund and Astellas Venture Management also...
08:00 , Dec 4, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Myocardial infarction (MI) SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily a member 5 (SMARCA5; SNF2H); farnesyltransferase CAAX box-b (FNTB); microRNA-99 (miR-99);...
08:00 , Jan 9, 2014 |  BC Innovations  |  Tools & Techniques

Silencing KRAS

Oncogenic KRAS is notoriously difficult to target because of a lack of well-defined surface pockets for drug binding. Nucleic acid therapeutics can bypass that issue but have their own problems including tissue targeting, cellular uptake...
08:00 , Dec 19, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Lin-28 homolog A (LIN28A)-dependent metabolic reprogramming for tissue repair Mouse studies suggest elevating LIN28A activity could help promote tissue regeneration after injury or in advanced...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Marina Biotech, Mirna deal

The companies partnered to develop microRNA-based targeted cancer therapies using Marina's SMARTICLES liposomal-based delivery technology and Mirna's miRNAs. Marina is eligible to receive up to $63 million total in upfront and milestone payments, as well...
07:00 , Apr 26, 2010 |  BC Week In Review  |  Clinical News

Regulus preclinical data

In a diet-induced obesity mouse model of diabetes, twice-weekly subcutaneous oligonucleotides targeting microRNA let-7 ( MIRLET7 ; LET-7 ) for 6 weeks improved insulin resistance by 75% as measured by insulin response during an oral...
07:00 , Jun 11, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Lin-28 homolog (LIN28); Lin-28 homolog B (LIN28B) In vitro studies suggest that targeting LIN28 and LIN28B could help treat cancer....
07:00 , Jun 1, 2009 |  BioCentury  |  Emerging Company Profile

Asuragen: Cutting pancreatic surgeries

Patients with pancreatic cancer and pancreatitis present with similar symptoms, and are often given ultrasound tests to confirm the presence or absence of lesions. About 15% of these tests are inconclusive, and as a result...
08:00 , Nov 20, 2008 |  BC Innovations  |  Tools & Techniques

Micromanaging oncolytic viruses

Oncolytic viruses have had limited success as cancer therapies, largely because of the need to balance potent antitumor activity with off-target toxicity. Two research teams have now applied a microRNA-based strategy that could restrict the...